Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Orgenesis's annualizedNet Income for the quarter that ended in Dec. 2021 was $-20.06 Mil. Orgenesis's average total tangible assets for the quarter that ended in Dec. 2021 was $42.17 Mil. Therefore, Orgenesis's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2021 was -47.58%.
The historical rank and industry rank for Orgenesis's Return-on-Tangible-Asset or its related term are showing as below:
ORGS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -19992 Med: -83.02 Max: 1.58
Current: -35.31
During the past 13 years, Orgenesis's highest Return-on-Tangible-Asset was 1.58%. The lowest was -19992.00%. And the median was -83.02%.
ORGS's Return-on-Tangible-Asset is ranked worse than 50.8% of 1557
companies
in the Biotechnology industry
Industry Median: -34.50
vs ORGS: -35.31
Orgenesis Return-on-Tangible-Asset Historical Data
The historical data trend for Orgenesis's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Orgenesis Annual Data
Trend
Nov12
Nov13
Nov14
Nov15
Nov16
Nov17
Nov18
Dec19
Dec20
Dec21
Return-on-Tangible-Asset
-106.49
-63.38
-37.71
1.58
-37.79
Orgenesis Quarterly Data
Feb17
May17
Aug17
Nov17
Feb18
May18
Aug18
Nov18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Return-on-Tangible-Asset
-231.84
-1.50
-18.44
-81.89
-47.58
Competitive Comparison
For the Biotechnology subindustry, Orgenesis's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orgenesis Return-on-Tangible-Asset Distribution
For the Biotechnology industry and Healthcare sector, Orgenesis's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Orgenesis's Return-on-Tangible-Asset falls into.
Orgenesis Return-on-Tangible-Asset Calculation
Orgenesis's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2021 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2021) net income data.
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companyÂ’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companyÂ’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Orgenesis Return-on-Tangible-Asset Related Terms
Thank you for viewing the detailed overview of Orgenesis's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.03(1.45%) Volume: 44,682 8:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ORGS has been successfully added to your 
